Medical
Technology Innovation Scorecard
|
PwC’s Medical Technology
Innovation Scorecard: The race for global leadership assesses nine
countries’ capacity and capability for medical technology innovation:
Brazil, China, France, Germany, India, Israel, Japan, United Kingdom, United
States.
Key findings :
-
The medical technology innovation
ecosystem, long centered in the United States, is moving offshore.
Innovators are going outside the United States to seek clinical data,
new-product registration, and first revenue.
-
US consumers aren’t always the first to
benefit from medical technology and could eventually be last. Innovators
already are going first to market in Europe and, by 2020, likely will move
into emerging countries next.
-
The nature of innovation is changing as
developing nations become the leading markets for smaller, faster, more
affordable devices that enable delivery of care anywhere at lower cost.
|
The United States continues to lead the world in its
capacity to produce the latest in medical technology innovation, but emerging
markets led by China, India and Brazil are catching up, and their market power
is shifting innovation resources and activity overseas, according to a new PwC
report Medical Technology Innovation Scorecard: The race for global leadership.
While the United States is expected to maintain its leadership for the
foreseeable future, even a narrowing of the gap has implications for U.S. jobs,
exports and Americans’ access to advances in medical technology.
The report is based on the findings of the PwC
Medical Technology Innovation Scorecard, a new, multifaceted assessment of the
capacity of countries to adapt to the changing nature of innovation. While there
has been much anecdotal evidence that the U.S. is losing ground as the world’s
innovation leader, PwC analyzed the specific factors that contribute to medical
technology innovation and quantified them, using 86 different metrics to
evaluate how well each nation promotes the factors that advance innovation. The
nine nations evaluated are Brazil, China, France, Germany, India, Israel, Japan,
the United Kingdom and the U.S.
In addition to providing a current view of
innovative capacity and capability in these countries, the Innovation Scorecard
looked at the past five years to gain a historical perspective and projected
into the future to present the outlook for medical technology innovation
leadership over the next decade to 2020.
A top-line view of current results of the Innovation
Scorecard reveals:
-
On a scale of 1 to 9, with 9 as the highest score,
the U.S. currently has a total score of 7.1 and is the global leader in medical
technology innovation. Because of decades of innovation dominance, the U.S.
continues to show the greatest capacity for medical technology innovation.
-
The scores of the other developed nations (the U.K.,
Germany, Japan and France) fall within a tight band of 4.8 to 5.4. Among the
developed countries included in this study, Germany and the U.K. demonstrate the
strongest support for innovation and Japan the weakest.
-
Israel, despite its small size, ranks near the level
of the European nations, which indicates its strong capacity to foster
innovation.
-
The emerging markets lag behind developed ones. China, with its powerful
economic growth engine, scores 3.4, ranking it higher than India and Brazil,
each of which scored 2.7.
Looking to the future, the U.S. is expected to
continue to lead in medical technology innovation, but also will lose ground to
other countries during the next decade. The Innovation Scorecard also projects
relative declines for Japan, Israel, France, the U.K. and Germany. By contrast,
China, India and Brazil are likely to see gains during the coming decade. China,
which has shown the largest improvement in its medical technology innovative
capacity during the past five years, is expected to continue to outpace other
countries and reach near-parity with the developed nations of Europe by 2020.
Page 1
2
|
|
